Miguel Jiménez-Gómez,Carlos Pablo de Fuenmayor-Fernández de la Hoz,Ana Hernández-Voth
Miguel Jiménez-Gómez
Georgie May Massen,Hannah Whittaker
Georgie May Massen
Performance of volume and diameter thresholds in malignancy prediction of solid nodules in lung cancer screening [0.03%]
基于体积和直径阈值的肺癌筛查实性结节恶性预测性能分析
Andrew W Creamer,Carolyn Horst,Ruth Prendecki et al.
Andrew W Creamer et al.
Background: Prospective validation and comparison of the performance of nodule management protocols is limited. The aim of this study was to examine the performance of size and risk thresholds for assessing malignancy in ...
Comparison of volume-based and diameter-based assessment of solid nodules in lung cancer screening [0.03%]
基于体积和直径的肺结节评估在肺癌筛查中的比较研究
Mark M Hammer
Mark M Hammer
Early phase clinical trials in pulmonary hypertension: how small is big enough? [0.03%]
肺动脉高压早期临床试验：多小的样本量才是足够大？
Steven D Nathan
Steven D Nathan
Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension [0.03%]
口服himecromone治疗成人肺动脉高压的随机、双盲和安慰剂对照试验
Kathryn Czepiel,Nadine Nagy,Tamera Panjalingam et al.
Kathryn Czepiel et al.
Background: Pulmonary hypertension (PH) is a progressive cardiopulmonary condition associated with increased morbidity and mortality. The extracellular matrix component hyaluronan (HA) is linked to vascular remodelling an...
Adapting for the future: what can we learn from REMAP-CAP and COVID-19 pandemic trials? [0.03%]
面向未来的方法学改进：REMAP-CAP和新冠肺炎试验能给我们带来哪些启示？
Heather L Clark,Daniel Clark Files
Heather L Clark
1-year physical activity coaching programme in lung transplant recipients: an RCT [0.03%]
肺移植受者一年身体活动指导计划：一项随机对照试验
Sofie Breuls,Astrid Blondeel,Marieke Wuyts et al.
Sofie Breuls et al.
Introduction: Most lung transplant (LTX) recipients do not meet physical activity (PA) guidelines. Interventions are needed as long-term inactivity is related to morbidity and mortality. We investigated the effect of a te...
Smart steps forward: the role of wearables in long-term rehabilitation after lung transplantation [0.03%]
智能可穿戴设备在肺移植术后长期康复中的作用
Miguel Jiménez-Gómez,Javier Sayas Catalan
Miguel Jiménez-Gómez
Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis [0.03%]
Elexacaftor-tezacaftor-ivacaftor对囊性纤维化系统炎症的影响
Rosemary E Maher,Urszula M Cytlak-Chaudhuri,Saad Aleem et al.
Rosemary E Maher et al.
Background: Despite significant clinical improvements, there is evidence of persisting airway inflammation in people with cystic fibrosis (CF) established on elexacaftor/tezacaftor/ivacaftor (ETI) therapy. As CF is a mult...